

In the Claims

Please amend claims 1, 8-13, 19, 149-157, and 163, and add new claims 164-165 as follows.

1. (currently amended) A pharmaceutical composition comprising:
an isolated polymer of less than 50 kilodaltons ~~composed entirely~~ consisting of identical repeating units, each unit and having at least two repeating a charge motifs, ~~wherein each repeating charge motif~~ is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino ~~moieties~~ moiety of one of the at least two repeating charge motifs ~~are~~ is separated by an intervening sequence of at least 32 Å from the positively charged free amino moiety of another charge motif, and wherein the ~~intervening sequence is neutral~~ charge motifs are separated by neutral units, and
a pharmaceutically acceptable carrier.
- 2.-5. (canceled)
6. (original) The composition of claim 1, wherein the polymer is a mixed polymer.
7. (original) The composition of claim 6, wherein the mixed polymer is a peptide-nucleic acid.
8. (currently amended) The composition of claim 1, wherein the polymer has at least 10 ~~repeating~~ charge motifs.
9. (currently amended) The composition of claim 1, wherein the polymer has at least 15 ~~repeating~~ charge motifs.

10. (currently amended) The composition of claim 1, wherein the polymer has at least 20 repeating charge motifs.
11. (currently amended) The composition of claim 1, wherein the positively charged free amino ~~moieties~~ moiety of one of the at least two repeating charge motifs ~~are~~ is separated by a distance of at least 115 Å from the positively charged free amino moiety of another charge motif.
12. (currently amended) The composition of claim 1, wherein the positively charged free amino ~~moieties~~ moiety of one of the at least two repeating charge motifs ~~are~~ is separated by a distance of at least 155 Å from the positively charged free amino moiety of another charge motif.
13. (currently amended) The composition of claim 1, wherein the positively charged free amino ~~moieties~~ moiety of one of the at least two repeating charge motifs ~~are~~ is separated by a distance of at least 200 Å from the positively charged free amino moiety of another charge motif.
14. (original) The composition of claim 1, wherein the polymer is a synthetic polypeptide.
15. (original) The composition of claim 1, wherein the polymer is a non-native polypeptide.
16. (original) The composition of claim 1, wherein the polymer is a polypeptide having at least one modified amino acid.
17. (original) The composition of claim 1, wherein the polymer is a polypeptide having at least ten modified amino acids.
18. (original) The composition of claim 1, wherein the polymer is a polypeptide having a positive to negative charge ratio of 1:1.
19. (currently amended) A pharmaceutical composition comprising:

an isolated polypeptide of less than 50 kilodaltons ~~composed entirely~~ consisting of identical repeating units, each unit and having ~~at least two repeating~~ a charge motifs, wherein ~~each repeating charge motif~~ is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino ~~moieties~~ moiety of one of the at ~~least two repeating~~ charge motifs ~~are~~ is separated by a distance of at least 8 amino acids from the positively charged amino moiety of another charge motif, and
a pharmaceutically acceptable carrier.

20-148. (canceled)

149. (currently amended) The composition of claim 19, wherein the polypeptide has at least 10 ~~repeating~~ charge motifs.

150. (currently amended) The composition of claim 19, wherein the polypeptide has at least 15 ~~repeating~~ charge motifs.

151. (currently amended) The composition of claim 19, wherein the polypeptide has at least 20 ~~repeating~~ charge motifs.

152. (currently amended) The composition of claim 19, wherein the positively charged free amino moiety and the negative charges charge of the each repeating charge motifs motif are separated by at least one neutral amino acid.

153. (currently amended) The composition of claim 19, wherein the positively charged free amino moiety and the negative charges charge of the each repeating charge motifs motif are separated by at least five neutral amino acids.

154. (currently amended) The composition of claim 19, wherein the positively charged free amino moiety and the negative charges charge of the each repeating charge motifs motif are on adjacent amino acids.
155. (currently amended) The composition of claim 19, wherein the positively charged free amino moieties moiety of one of the at least two repeating charge motifs are is separated by a distance of at least 27 amino acids from the positively charged free amino moiety of another charge motif.
156. (currently amended) The composition of claim 19, wherein the positively charged free amino moieties moiety of one of the at least two repeating charge motifs are is separated by a distance of at least 37 amino acids from the positively charged free amino moiety of another charge motif.
157. (currently amended) The composition of claim 19, wherein the positively charged free amino moieties moiety of one of the at least two repeating charge motifs are is separated by a distance of at least 47 amino acids from the positively charged free amino moiety of another charge motif.
158. (previously presented) The composition of claim 19, wherein the polypeptide is a synthetic polypeptide.
159. (previously presented) The composition of claim 19, wherein the polypeptide is a non-native polypeptide.
160. (previously presented) The composition of claim 19, wherein the polypeptide has at least one modified amino acid.

161. (previously presented) The composition of claim 19, wherein the polypeptide has at least ten modified amino acids.
162. (previously presented) The composition of claim 19, wherein the polypeptide has a positive to negative charge ratio of 1:1.
163. (currently amended) The composition of claim 19, wherein ~~the~~ amino acids separating ~~the charged repeats~~ charge motifs are neutral amino acids.
164. (new) The composition of claim 19, wherein the polypeptide consists of (K-D)_n, wherein K is lysine, D is aspartic acid, and n is an integer greater than or equal to 10.
165. (new) The composition of claim 19, wherein the polypeptide consists of (K-D)_n, wherein K is lysine, D is aspartic acid, and n is an integer greater than or equal to 15.